Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

65
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
65
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

514
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
514
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

344
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
344
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

106
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
106
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

4.0K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.0K
Infection01:20

Infection

8.5K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STN-DBS and LCIG differentially affect long-term axial symptoms in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026
Same author

"<i>To Bean or Not to Bean</i>": Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about <i>Mucuna pruriens</i>.

Journal of Parkinson's disease·2026
Same author

Sex Differences in Levodopa-Sparing Effect of Safinamide: Post-hoc Findings from a Multicenter, Longitudinal, Case-Control Study.

Movement disorders clinical practice·2026
Same author

Gender differences in non-motor symptoms in Parkinson's disease: a multicenter longitudinal study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Chronic adaptive deep brain stimulation in Parkinson's disease: ADAPT-START findings and programming principles.

NPJ Parkinson's disease·2026

Related Experiment Video

Updated: Aug 9, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

28.7K

Disease mechanisms as subtypes: Microbiome.

Salvatore Bonvegna1, Roberto Cilia1

  • 1Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.

Handbook of Clinical Neurology
|February 21, 2023
PubMed
Summary

Gut microbiota changes are linked to Parkinson's disease (PD) progression. Understanding gut dysbiosis mechanisms and targeting it may offer new therapeutic strategies for PD.

Keywords:
Gut microbiotaGut–brain axisLevodopaNeuroinflammationParkinson's diseaseShort-chain fatty acids

More Related Videos

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.7K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K

Related Experiment Videos

Last Updated: Aug 9, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

28.7K
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.7K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K

Area of Science:

  • Microbiology
  • Neuroscience
  • Gastroenterology

Background:

  • Gut microbiota abnormalities are implicated in Parkinson's disease (PD) pathophysiology.
  • Gastrointestinal non-motor symptoms preceding motor deficits suggest gut dysbiosis role in neuroinflammation and alpha-synuclein aggregation.

Approach:

  • Analysis of healthy gut microbiota composition and influencing factors (environmental, genetic).
  • Investigation of gut dysbiosis mechanisms, mucosal barrier alterations, neuroinflammation, and alpha-synuclein aggregation.
  • Examination of gut microbiota alterations in PD patients across gastrointestinal tracts and their association with clinical features.

Key Points:

  • Gut dysbiosis contributes to neuroinflammation and alpha-synuclein aggregation in Parkinson's disease.
  • Specific gut microbiota alterations are observed in PD patients, correlating with clinical symptoms.
  • Therapeutic strategies targeting gut dysbiosis show potential for PD risk reduction and disease modification.

Conclusions:

  • Gut dysbiosis is a significant factor in Parkinson's disease development and progression.
  • Targeting gut microbiota offers promising avenues for novel therapeutic interventions in PD.
  • Further research is needed to personalize microbiome-based treatments for Parkinson's disease.